NCT06717113RecruitingEarly phase 1
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Clinical PET Imaging Evaluation of 68Ga-BC1 Probe in Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 6 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 28 Sept 2024
- Start date
- 15 Apr 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Peking University First Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT06717113
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 50
- From 15 Apr 2025 to the primary completion date, 31 Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant women; individuals unable to understand the examination process or who are unable to cooperate.
Who the study is looking for
- Suspected multiple myeloma patients scheduled for bone marrow aspiration or tissue biopsy within the past 3 months; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination.
- Diagnosed symptomatic multiple myeloma patients; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Enrolling by invitation |
| Department of Nuclear Medicine, Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
Related publications
- A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.J Clin Invest · 2026 · PMID 42378054
This page is information, not medical advice. Discuss any trial with your doctor.